m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00454)
Target Name Zinc finger MYM-type protein 1 (ZMYM1)
Gene Name ZMYM1
Chromosomal Location 1p34.3
Gene ID 79830
Uniprot ID
ZMYM1_HUMAN
HGNC ID
HGNC:26253
Ensembl Gene ID
ENSG00000197056
KEGG ID
hsa:79830
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
ZMYM1 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line Liver Mus musculus
Treatment: Mettl3 knockout liver
Control: Wild type liver cells
 GSE198513
Regulation
logFC: 7.91E-01
p-value: 6.45E-05
More Results Click to View More RNA-seq Results
Representative RIP-seq result supporting the interaction between ZMYM1 and the regulator
Cell Line MDA-MB-231 Homo sapiens
Regulation logFC: 1.20E+00 GSE60213
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary The m6A modification of Zinc finger MYM-type protein 1 (ZMYM1) mRNA by METTL3 enhanced its stability relying on the "reader" protein HuR (also known as ELAVL1) dependent pathway.The study uncover METTL3/ZMYM1/E-cadherin signaling as a potential therapeutic target in anti-metastatic strategy against Gastric cancer.
Target Regulation Up regulation
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
Pathway Response Cytokine-cytokine receptor interaction hsa04060
Cell Process Epithelial-mesenchymal transition
In-vitro Model AGS Gastric adenocarcinoma Homo sapiens CVCL_0139
BGC-823 Gastric carcinoma Homo sapiens CVCL_3360
GES-1 Normal Homo sapiens CVCL_EQ22
MGC-803 Gastric mucinous adenocarcinoma Homo sapiens CVCL_5334
MKN28 Gastric tubular adenocarcinoma Homo sapiens CVCL_1416
SGC-7901 Gastric carcinoma Homo sapiens CVCL_0520
In-vivo Model The luciferase signal intensity from days 7 to 42 is on equivalent scales in the models. Bioluminescent flux (photons/s/cm2/steradian) was determined for the lung metastases.
Gastric cancer [ICD-11: 2B72]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary The m6A modification of Zinc finger MYM-type protein 1 (ZMYM1) mRNA by METTL3 enhanced its stability relying on the "reader" protein HuR (also known as ELAVL1) dependent pathway.The study uncover METTL3/ZMYM1/E-cadherin signaling as a potential therapeutic target in anti-metastatic strategy against Gastric cancer.
Responsed Disease Gastric cancer [ICD-11: 2B72]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Cytokine-cytokine receptor interaction hsa04060
Cell Process Epithelial-mesenchymal transition
In-vitro Model AGS Gastric adenocarcinoma Homo sapiens CVCL_0139
BGC-823 Gastric carcinoma Homo sapiens CVCL_3360
GES-1 Normal Homo sapiens CVCL_EQ22
MGC-803 Gastric mucinous adenocarcinoma Homo sapiens CVCL_5334
MKN28 Gastric tubular adenocarcinoma Homo sapiens CVCL_1416
SGC-7901 Gastric carcinoma Homo sapiens CVCL_0520
In-vivo Model The luciferase signal intensity from days 7 to 42 is on equivalent scales in the models. Bioluminescent flux (photons/s/cm2/steradian) was determined for the lung metastases.
References
Ref 1 METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer. 2019 Oct 13;18(1):142. doi: 10.1186/s12943-019-1065-4.